Profile data is unavailable for this security.
About the company
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).
- Revenue in USD (TTM)95.84m
- Net income in USD-80.85m
- Incorporated2015
- Employees135.00
- LocationGossamer Bio Inc3013 Science Park RdSAN DIEGO 92121-1101United StatesUSA
- Phone+1 (858) 922-0718
- Fax+1 (302) 636-5454
- Websitehttps://www.gossamerbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zentalis Pharmaceuticals Inc | 40.56m | -194.65m | 221.15m | 168.00 | -- | 0.578 | -- | 5.45 | -2.75 | -2.75 | 0.5719 | 5.38 | 0.0729 | -- | 15.94 | 241,428.60 | -34.99 | -47.40 | -39.16 | -54.18 | -- | -- | -480.07 | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| Codexis Inc | 60.89m | -76.36m | 221.29m | 174.00 | -- | 3.60 | -- | 3.63 | -1.09 | -1.09 | 0.8723 | 0.8665 | 0.3595 | 6.27 | 3.58 | 349,942.50 | -45.08 | -17.13 | -56.05 | -20.23 | 77.95 | 77.29 | -125.41 | -37.04 | 2.92 | -- | 0.3158 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| Fulcrum Therapeutics Inc | 81.63m | -20.23m | 222.77m | 76.00 | -- | 0.8117 | -- | 2.73 | -0.3507 | -0.3507 | 1.31 | 4.40 | 0.2746 | -- | 29.13 | 1,074,079.00 | -6.81 | -50.55 | -7.14 | -55.91 | -- | -- | -24.79 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| Omeros Corp | 0.00 | -199.92m | 223.10m | 198.00 | -- | -- | -- | -- | -3.32 | -2.35 | 0.00 | -2.15 | 0.00 | -- | -- | 0.00 | -45.24 | -55.51 | -58.74 | -70.10 | -- | -- | -- | -- | -- | -5.74 | 1.42 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
| MacroGenics Inc | 41.02m | -136.37m | 225.17m | 339.00 | -- | 3.89 | -- | 5.49 | -2.19 | -2.19 | 0.6583 | 0.9218 | 0.1619 | 6.62 | 6.51 | 120,997.00 | -53.82 | -37.76 | -67.56 | -45.53 | 79.37 | -- | -332.47 | -133.96 | 2.69 | -172.62 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -34.97m | 228.71m | 19.00 | -- | 1.74 | -- | -- | -5.82 | -5.82 | 0.00 | 10.92 | 0.00 | -- | -- | 0.00 | -35.74 | -86.84 | -45.03 | -130.46 | -- | -- | -- | -769.76 | -- | -29.78 | 0.0794 | -- | -- | -- | -5.33 | -- | -- | -- |
| Adaptimmune Therapeutics PLC - ADR | 141.46m | -72.50m | 232.73m | 449.00 | -- | 2.42 | -- | 1.65 | -0.3452 | -0.3452 | 0.5922 | 0.3765 | 0.4256 | -- | 53.33 | 315,053.40 | -21.81 | -41.19 | -28.63 | -48.21 | -- | -- | -51.25 | -714.26 | -- | -- | 0.2058 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| Nektar Therapeutics | 93.16m | -177.08m | 235.62m | 137.00 | -- | 2.96 | -- | 2.53 | -0.9007 | -0.9007 | 0.4747 | 0.4329 | 0.2224 | 2.16 | 73.61 | 679,978.10 | -42.28 | -31.02 | -48.54 | -34.63 | 59.22 | 78.04 | -190.09 | -372.21 | 4.90 | -18.76 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| Amarin Corporation plc (ADR) | 264.78m | -33.52m | 236.74m | 275.00 | -- | 0.4292 | -- | 0.8941 | -0.082 | -0.082 | 0.6466 | 1.34 | 0.319 | 0.4395 | 2.15 | 962,832.80 | -4.04 | -4.48 | -5.79 | -6.54 | 61.29 | 75.70 | -12.66 | -8.59 | 2.01 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| Gossamer Bio Inc | 95.84m | -80.85m | 237.54m | 135.00 | -- | 2.91 | -- | 2.48 | -0.3996 | -0.3996 | 0.434 | 0.3604 | 0.3453 | -- | -- | 709,940.80 | -29.13 | -57.43 | -34.41 | -64.38 | -- | -- | -84.36 | -- | -- | -7.07 | 0.7073 | -- | -- | -- | 21.61 | -- | -- | -- |
| Jasper Therapeutics Inc | 0.00 | -62.44m | 239.42m | 45.00 | -- | 2.39 | -- | -- | -5.10 | -5.10 | 0.00 | 6.64 | 0.00 | -- | -- | 0.00 | -52.45 | -- | -57.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| Mersana Therapeutics Inc | 29.94m | -104.77m | 240.44m | 123.00 | -- | 28.53 | -- | 8.03 | -0.8648 | -0.8648 | 0.2469 | 0.0687 | 0.1222 | -- | 38.14 | 243,390.30 | -42.75 | -61.68 | -59.36 | -81.35 | -- | -- | -349.98 | -622.19 | -- | -- | 0.7508 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Enanta Pharmaceuticals Inc | 71.96m | -115.33m | 244.73m | 145.00 | -- | 1.64 | -- | 3.40 | -5.46 | -5.46 | 3.41 | 7.03 | 0.161 | -- | 5.32 | 496,275.90 | -25.80 | -14.56 | -30.05 | -15.62 | -- | -- | -160.27 | -54.96 | -- | -- | 0.0095 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| 2Seventy Bio Inc | 44.12m | -156.25m | 247.19m | 274.00 | -- | 1.05 | -- | 5.60 | -3.06 | -3.06 | 0.8417 | 4.56 | 0.0721 | -- | 1.42 | 161,021.90 | -25.54 | -- | -28.17 | -- | 66.39 | 91.76 | -354.16 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Chromadex Corp | 85.58m | -1.35m | 252.10m | 106.00 | -- | 8.16 | -- | 2.95 | -0.018 | -0.018 | 1.14 | 0.407 | 1.60 | 2.86 | 12.93 | 807,386.80 | -2.52 | -42.11 | -3.85 | -65.14 | 60.82 | 59.68 | -1.58 | -30.64 | 2.12 | -- | 0.0006 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
Data as of Oct 08 2024. Currency figures normalised to Gossamer Bio Inc's reporting currency: US Dollar USD
36.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invus Public Equities Advisors LLCas of 25 Jul 2024 | 13.31m | 5.88% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 11.70m | 5.17% |
| EcoR1 Capital, LLCas of 31 Mar 2024 | 9.20m | 4.07% |
| Octagon Capital Advisors LPas of 31 Mar 2024 | 9.19m | 4.06% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 8.19m | 3.62% |
| Millennium Management LLCas of 31 Mar 2024 | 6.50m | 2.87% |
| Palo Alto Investors LPas of 31 Mar 2024 | 6.39m | 2.83% |
| Farallon Capital Management LLCas of 31 Mar 2024 | 6.13m | 2.71% |
| SilverArc Capital Management LLCas of 31 Mar 2024 | 6.13m | 2.71% |
| Eversept Partners LPas of 31 Mar 2024 | 5.99m | 2.65% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
